BioCentury
ARTICLE | Company News

IPR petitions target Oracea, Kerydin

August 22, 2015 2:01 AM UTC

Rosacea drug Oracea doxycycline from Galderma S.A. (Lausanne, Switzerland) and onychomycosis drug Kerydin tavaborole from Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) were the targets of several new inter partes review (IPR) petitions filed with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office.

Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) filed three IPR petitions challenging Galderma's U.S. Patent No. 8,603,506, which covers Oracea's method of use to treat rosacea and expires in 2022. The patent is one of 11 Orange Book-listed patents covering the once-daily modified-release formulation of doxycycline; the last patent expires in 2027. Oracea uses drug delivery technology from Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), which receives royalties from Oracea sales. ...